Initial Management of Aortoiliac Atherosclerotic Calcifications

Core Medical Management

The American College of Cardiology recommends initiating single-agent antiplatelet therapy, such as aspirin 75-325 mg daily, to reduce major adverse cardiovascular events and cardiovascular mortality in all symptomatic PAD patients 1, 3, 4
The American Heart Association recommends considering rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily, as this combination has been shown to reduce cardiovascular death, myocardial infarction, or stroke compared with aspirin alone 1
The European Society of Cardiology recommends cilostazol 100 mg twice daily to improve walking distance in patients with intermittent claudication 3
The American College of Cardiology recommends prescribing high-dose statin therapy for all patients with PAD to reduce cardiovascular events and improve outcomes 1, 3
The American Heart Association recommends administering antihypertensive therapy to all patients with hypertension and PAD to reduce the risk of major adverse cardiovascular events 1, 3

The American College of Cardiology recommends initiating a supervised exercise program in all patients with non-limb-threatening PAD to improve maximum walking distance, reduce overall mortality, and decrease the need for secondary revascularization procedures 1, 3, 4
Multiple randomized controlled trials have demonstrated significant improvement in disease-specific quality of life measurements, walking distance, and treadmill walking performance following supervised exercise therapy 3

The Society of Interventional Radiology recommends obtaining duplex ultrasound imaging of the aortoiliac segment and lower extremities to establish concordance between clinical symptoms and peripheral arterial disease (PAD) 4
The American College of Cardiology recommends measuring ankle-brachial index (ABI) and obtaining lipid profile for comprehensive risk factor analysis 4

The American Heart Association recommends reserving intervention for patients with lifestyle-limiting claudication that fails to improve with optimal medical management and supervised exercise therapy, or for those with critical limb-threatening ischemia (CLTI) 2, 4
The European Society of Cardiology recommends an endovascular-first approach for TASC C and D lesions due to high success rates, low morbidity and mortality, and similar long-term patency to open surgery 1, 2, 3
Covered balloon-expandable stents demonstrate significantly higher patency rates than bare metal stents at 18, 24, 48, and 60 months 1, 5

The Society of Interventional Radiology recommends addressing concomitant superficial femoral artery (SFA) stenosis >50% at the time of iliac intervention, as this is a predictor of iliac intervention failure 5
The American Heart Association recommends discussing tobacco cessation with all patients, despite retrospective data showing no significant increase in reintervention or limb loss in smokers versus nonsmokers 1, 3
Surgical revascularization carries 30-day mortality of 3.6% and major complication rate of 20%, and should be reserved for patients who fail endovascular therapy or have disease not amenable to endovascular treatment 2, 4